Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Progression-Free Survival"" wg kryterium: Temat


Tytuł:
Pomalidomide combinations are a safe and effective option after daratumumab failure.
Autorzy:
Brioli A; Klinik für Innere Medizin C, Universitätsmedizin Greifswald, Greifswald, Germany. .; Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany. .
Gengenbach L; Hämatologie und Onkologie, Faculty of Freiburg, Universität Freiburg, Freiburg, Germany.
Mancuso K; Istituto di Ematologia 'Seràgnoli', IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
Binder M; Klinik für Innere Medizin IV, Onkologie und Hämatologie, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Germany.
Ernst T; Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
Heidel FH; Klinik für Innere Medizin C, Universitätsmedizin Greifswald, Greifswald, Germany.
Stauch T; Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
Zamagni E; Istituto di Ematologia 'Seràgnoli', IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
Hilgendorf I; Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
Hochhaus A; Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
Engelhardt M; Hämatologie und Onkologie, Faculty of Freiburg, Universität Freiburg, Freiburg, Germany.
von Lilienfeld-Toal M; Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
Pokaż więcej
Źródło:
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2023 Aug; Vol. 149 (9), pp. 6569-6574. Date of Electronic Publication: 2023 Feb 13.
Typ publikacji:
Journal Article
MeSH Terms:
Angiogenesis Inhibitors*/therapeutic use
Antibodies, Monoclonal*/therapeutic use
Antineoplastic Agents*/therapeutic use
Multiple Myeloma*/drug therapy
Thalidomide*/therapeutic use
Progression-Free Survival*
Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Drug Therapy, Combination ; Recurrence ; Salvage Therapy ; Treatment Failure
Czasopismo naukowe
Tytuł:
The impact of smoking on recurrence and progression of non-muscle invasive bladder cancer: a systematic review and meta-analysis.
Autorzy:
Ślusarczyk A; Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. .
Zapała P; Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. .
Zapała Ł; Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland.
Radziszewski P; Department of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland.
Pokaż więcej
Źródło:
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2023 Jun; Vol. 149 (6), pp. 2673-2691. Date of Electronic Publication: 2022 Nov 21.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Smoking*/adverse effects
Neoplasm Recurrence, Local*/mortality
Neoplasm Recurrence, Local*/pathology
Non-Muscle Invasive Bladder Neoplasms*/mortality
Non-Muscle Invasive Bladder Neoplasms*/pathology
Progression-Free Survival*
Humans
Czasopismo naukowe
Tytuł:
Tumor and metastatic lymph nodes metabolic activity on F-FDG-PET/CT to predict progression-free survival in locally advanced cervical cancer.
Autorzy:
Song J; Department of Nuclear Medicine, Zhejiang Provincial Research Center for Cancer Intelligent Diagnosis and Molecular Technology (JBZX-202003), Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, No. 1, East Banshan Road, Gongshu District, Hangzhou, 310022, Zhejiang, People's Republic of China.
Pang W; Department of Nuclear Medicine, Zhejiang Provincial Research Center for Cancer Intelligent Diagnosis and Molecular Technology (JBZX-202003), Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, No. 1, East Banshan Road, Gongshu District, Hangzhou, 310022, Zhejiang, People's Republic of China.
Yi H; Department of Nuclear Medicine, Zhejiang Provincial Research Center for Cancer Intelligent Diagnosis and Molecular Technology (JBZX-202003), Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, No. 1, East Banshan Road, Gongshu District, Hangzhou, 310022, Zhejiang, People's Republic of China.
Ji J; Department of Nuclear Medicine, Zhejiang Provincial Research Center for Cancer Intelligent Diagnosis and Molecular Technology (JBZX-202003), Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, No. 1, East Banshan Road, Gongshu District, Hangzhou, 310022, Zhejiang, People's Republic of China.
Ye X; Department of Nuclear Medicine, Zhejiang Provincial Research Center for Cancer Intelligent Diagnosis and Molecular Technology (JBZX-202003), Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, No. 1, East Banshan Road, Gongshu District, Hangzhou, 310022, Zhejiang, People's Republic of China.
Li L; Department of Nuclear Medicine, Zhejiang Provincial Research Center for Cancer Intelligent Diagnosis and Molecular Technology (JBZX-202003), Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, No. 1, East Banshan Road, Gongshu District, Hangzhou, 310022, Zhejiang, People's Republic of China. .
Pokaż więcej
Źródło:
Abdominal radiology (New York) [Abdom Radiol (NY)] 2024 Mar; Vol. 49 (3), pp. 975-984. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Journal Article
MeSH Terms:
Positron Emission Tomography Computed Tomography*
Uterine Cervical Neoplasms*/diagnostic imaging
Uterine Cervical Neoplasms*/therapy
Female ; Humans ; Middle Aged ; Adult ; Aged ; Aged, 80 and over ; Fluorodeoxyglucose F18 ; Carcinoembryonic Antigen ; Progression-Free Survival ; Radiopharmaceuticals ; Disease Progression ; Lymph Nodes/diagnostic imaging ; Lymph Nodes/pathology ; Tumor Burden ; Prognosis ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer.
Autorzy:
Chiu LC; Department of Thoracic Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Hsu PC; Department of Thoracic Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Wang CC; Division of Pulmonary & Critical Care Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Ko HW; Department of Thoracic Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Kuo SC; Department of Thoracic Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Ju JS; Department of Thoracic Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Tung PH; Department of Thoracic Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Huang AC; Department of Thoracic Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Yang CT; Department of Thoracic Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.; Department of Internal Medicine, Taoyuan Chang Gung Memorial Hospital, Taoyuan, Taiwan.; Department of Respiratory Therapy, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 Mar; Vol. 15 (7), pp. 529-537. Date of Electronic Publication: 2024 Jan 26.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Liver Neoplasms*
Humans ; Afatinib/therapeutic use ; Progression-Free Survival ; Retrospective Studies ; ErbB Receptors/genetics ; Mutation ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł:
Predicting the progression-free survival of gastrointestinal stromal tumors after imatinib therapy through multi-sequence magnetic resonance imaging.
Autorzy:
Yang L; Department of Medical Imaging, The First Hospital of Qinhuangdao, Qinhuangdao, People's Republic of China.
Zhang D; Department of Medical Imaging, Baoding No. 1 Central Hospital, Baoding, People's Republic of China.
Zheng T; Department of Medical Imaging, The First Hospital of Qinhuangdao, Qinhuangdao, People's Republic of China.
Liu D; Department of Medical Imaging, The First Hospital of Qinhuangdao, Qinhuangdao, People's Republic of China. .
Fang Y; Medical Imaging Center, Chongqing Yubei District People's Hospital, Chongqing, People's Republic of China. .
Pokaż więcej
Źródło:
Abdominal radiology (New York) [Abdom Radiol (NY)] 2024 Mar; Vol. 49 (3), pp. 801-813. Date of Electronic Publication: 2023 Nov 25.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Gastrointestinal Stromal Tumors*/diagnostic imaging
Gastrointestinal Stromal Tumors*/drug therapy
Female ; Humans ; Male ; Middle Aged ; Imatinib Mesylate/therapeutic use ; Magnetic Resonance Imaging/methods ; Progression-Free Survival ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies.
Autorzy:
Shahnam A; Department of Medical Oncology, Peter McCallum Cancer Centre, Melbourne, VIC, Australia. Electronic address: .
Hitchen N; Department of Medical Oncology, Peter McCallum Cancer Centre, Melbourne, VIC, Australia.
Nindra U; Department of Medical Oncology, Liverpool Hospital, Sydney, New South Wales, Australia.
Manoharan S; Department of Medical Oncology, Peter McCallum Cancer Centre, Melbourne, VIC, Australia.
Desai J; Department of Medical Oncology, Peter McCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.
Tran B; Department of Medical Oncology, Peter McCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.
Solomon B; Department of Medical Oncology, Peter McCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.
Luen SJ; Department of Medical Oncology, Peter McCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.
Hui R; The Centre of Cancer Medicine, University Hong Kong, Hong Kong.
Hopkins AM; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
Sorich MJ; College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
Pokaż więcej
Źródło:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Feb; Vol. 198, pp. 113503. Date of Electronic Publication: 2023 Dec 18.
Typ publikacji:
Meta-Analysis; Journal Article
MeSH Terms:
Melanoma*
Pancreatic Neoplasms*/drug therapy
Humans ; Biomarkers ; Disease-Free Survival ; Progression-Free Survival ; Randomized Controlled Trials as Topic ; Clinical Trials, Phase III as Topic
Czasopismo naukowe
Tytuł:
2018 Leibovich prognostic model for renal cell carcinoma: Performance in a large population with special consideration of Black race.
Autorzy:
Schmeusser BN; Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Patil DH; Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA.
Nicaise EH; Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA.
Armas-Phan M; Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA.
Nabavizadeh R; Department of Urology, Mayo Clinic, Rochester, Minnesota, USA.
Narayan VM; Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA.; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Joshi SS; Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA.; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Ogan K; Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA.
Osunkoya AO; Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA.; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.; Department of Pathology, Emory University School of Medicine, Atlanta, Georgia, USA.
Bilen MA; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
Master VA; Department of Urology, Emory University School of Medicine, Atlanta, Georgia, USA.; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Pokaż więcej
Źródło:
Cancer [Cancer] 2024 Feb 01; Vol. 130 (3), pp. 453-466. Date of Electronic Publication: 2023 Oct 06.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Renal Cell*/pathology
Kidney Neoplasms*/pathology
Humans ; Prognosis ; Progression-Free Survival ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Development and validation of a F-FDG PET/CT radiomics nomogram for predicting progression free survival in locally advanced cervical cancer: a retrospective multicenter study.
Autorzy:
Liu H; Department of Radiation Oncology, The Third Affillated Teaching Hospital of Xinjiang Medical University, Affilated Cancer Hospital, Urumuqi, China.
Cui Y; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China.
Chang C; Department of Nuclear Medicine, Third Affiliated Hospital of Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Urumqi, China.
Zhou Z; School of Mechanical, Electrical and Information Engineering, Shandong University, Weihai, China.
Zhang Y; Department of Radiation Oncology, The Third Affillated Teaching Hospital of Xinjiang Medical University, Affilated Cancer Hospital, Urumuqi, China.; Xinjiang Key Laboratory of Oncology, Urumqi, China.; Key Laboratory of Cancer Immunotherapy and Radiotherapy, Chinese Academy of Medical Sciences, Urumqi, China.
Ma C; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China.
Yin Y; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China. .
Wang R; Department of Radiation Oncology, The Third Affillated Teaching Hospital of Xinjiang Medical University, Affilated Cancer Hospital, Urumuqi, China. .; Xinjiang Key Laboratory of Oncology, Urumqi, China. .; Key Laboratory of Cancer Immunotherapy and Radiotherapy, Chinese Academy of Medical Sciences, Urumqi, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Jan 30; Vol. 24 (1), pp. 150. Date of Electronic Publication: 2024 Jan 30.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Nomograms*
Uterine Cervical Neoplasms*/diagnostic imaging
Uterine Cervical Neoplasms*/therapy
Female ; Humans ; Fluorodeoxyglucose F18 ; Positron Emission Tomography Computed Tomography ; Progression-Free Survival ; Radiomics ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Prognosis and conditional survival among women with newly diagnosed ovarian cancer.
Autorzy:
Szamreta EA; Center for Observational & Real-World Evidence (CORE), Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065, USA. Electronic address: .
Monberg MJ; Center for Observational & Real-World Evidence (CORE), Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065, USA. Electronic address: .
Desai KD; Center for Observational & Real-World Evidence (CORE), Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065, USA. Electronic address: .
Li Y; Center for Observational & Real-World Evidence (CORE), Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065, USA. Electronic address: .
Othus M; Fred Hutchinson Cancer Center, 1100 Fairview Ave N, Seattle, WA 98109, USA. Electronic address: .
Pokaż więcej
Źródło:
Gynecologic oncology [Gynecol Oncol] 2024 Jan; Vol. 180, pp. 170-177. Date of Electronic Publication: 2024 Jan 10.
Typ publikacji:
Journal Article
MeSH Terms:
Ovarian Neoplasms*/drug therapy
Humans ; Female ; Prognosis ; Progression-Free Survival ; Survival Rate ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities.
Autorzy:
Guman T
Sykora J
Pokaż więcej
Źródło:
Bratislavske lekarske listy [Bratisl Lek Listy] 2024; Vol. 125 (1), pp. 9-11.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/methods
Multiple Myeloma*/genetics
Multiple Myeloma*/therapy
Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chromosome Aberrations ; Disease Progression ; Disease-Free Survival ; Progression-Free Survival ; Retrospective Studies ; Stem Cell Transplantation ; Transplantation, Autologous ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Attitudes of healthcare professionals and drug regulators about progression-free survival as endpoint in the advanced cancer setting.
Autorzy:
Postmus D; European Medicines Agency, Amsterdam, the Netherlands; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, the Netherlands.
Litiere S; European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
Bogaerts J; European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
Versluis J; Erasmus Medical Center Cancer Institute, Department of Hematology, Rotterdam, the Netherlands.
Cornelissen JJ; European Medicines Agency, Amsterdam, the Netherlands; Erasmus Medical Center Cancer Institute, Department of Hematology, Rotterdam, the Netherlands.
Pignatti F; European Medicines Agency, Amsterdam, the Netherlands. Electronic address: .
Pokaż więcej
Źródło:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Jan; Vol. 197, pp. 113496. Date of Electronic Publication: 2023 Dec 15.
Typ publikacji:
Journal Article
MeSH Terms:
Neoplasms*/drug therapy
Humans ; Progression-Free Survival ; Cross-Sectional Studies ; Health Personnel ; Delivery of Health Care ; Disease-Free Survival
Czasopismo naukowe
Tytuł:
Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study.
Autorzy:
Gordan LN; Florida Cancer Specialists & Research Institute, Gainesville, FL, USA. Electronic address: .
Tan CR; Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
Vescio R; Samuel Oschin Cancer Center, Cedars-Sinai, Los Angeles, CA, USA.
Ye JC; University of Michigan, Ann Arbor, MI, USA.
Schinke C; University of Arkansas, Fayetteville, AR, USA.
Medhekar R; Janssen Scientific Affairs, LLC, Horsham, PA, USA.
Fu AZ; Janssen Scientific Affairs, LLC, Titusville, NJ, USA; Georgetown University Medical Center, Washington, DC, USA.
Lafeuille MH; Analysis Group, Inc., Montreal, Quebec, Canada.
Thompson-Leduc P; Analysis Group, Inc., Montreal, Quebec, Canada.
Khare V; Janssen Scientific Affairs, LLC, Horsham, PA, USA.
Reitan J; RJM Group, LLC, Chicago, IL, USA.
Milkovich G; RJM Group, LLC, Washington, DC, USA.
Kaila S; Janssen Scientific Affairs, LLC, Horsham, PA, USA.
Davies F; Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Usmani SZ; Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
Pokaż więcej
Źródło:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Jan; Vol. 24 (1), pp. 55-63. Date of Electronic Publication: 2023 Sep 14.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Antibodies, Monoclonal*
Multiple Myeloma*/therapy
Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bortezomib/therapeutic use ; Dexamethasone/therapeutic use ; Disease Progression ; Lenalidomide/therapeutic use ; Progression-Free Survival ; Aged ; Clinical Trials as Topic
Czasopismo naukowe
Tytuł:
Progression-free survival assessment by local investigators versus blinded independent central review in randomized clinical trials in metastatic breast cancer: A systematic review and meta-analysis.
Autorzy:
Jacobs F; Université Libre de Bruxelles (U.L.B), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Academic Trials Promoting Team (ATPT), Brussels, Belgium; Humanitas Clinical and Research Center - IRCCS, Humanitas Cancer Center, via Manzoni 56, 20089 Rozzano, Milan, Italy.
Molinelli C; Université Libre de Bruxelles (U.L.B), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Academic Trials Promoting Team (ATPT), Brussels, Belgium; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy.
Martins-Branco D; Université Libre de Bruxelles (U.L.B), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Academic Trials Promoting Team (ATPT), Brussels, Belgium.
Marta GN; Université Libre de Bruxelles (U.L.B), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Academic Trials Promoting Team (ATPT), Brussels, Belgium.
Salmon M; Université Libre de Bruxelles (U.L.B), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Data Center, Brussels, Belgium.
Ameye L; Université Libre de Bruxelles (U.L.B), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Data Center, Brussels, Belgium.
Piccart M; Université Libre de Bruxelles (U.L.B), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Medical Oncology Department, Brussels, Belgium.
Lambertini M; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy; Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Agostinetto E; Université Libre de Bruxelles (U.L.B), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Academic Trials Promoting Team (ATPT), Brussels, Belgium. Electronic address: .
de Azambuja E; Université Libre de Bruxelles (U.L.B), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Academic Trials Promoting Team (ATPT), Brussels, Belgium. Electronic address: .
Pokaż więcej
Źródło:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Jan; Vol. 197, pp. 113478. Date of Electronic Publication: 2023 Dec 12.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Humans ; Female ; Progression-Free Survival ; Disease-Free Survival ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł:
Multiparametric MRI-based fusion radiomics for predicting telomerase reverse transcriptase (TERT) promoter mutations and progression-free survival in glioblastoma: a multicentre study.
Autorzy:
Zhang H; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, China.; Department of Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, #106 Zhongshan 2Nd Road, Guangzhou, 510080, China.; Department of Radiology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 517108, China.
Zhang H; Department of Radiology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, #3002 SunGangXi Road, Shenzhen, 518035, China.
Zhang Y; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, China.; Department of Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, #106 Zhongshan 2Nd Road, Guangzhou, 510080, China.
Zhou B; Department of Radiology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 517108, China.
Wu L; Department of Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, #106 Zhongshan 2Nd Road, Guangzhou, 510080, China.
Yang W; Department of Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, #106 Zhongshan 2Nd Road, Guangzhou, 510080, China.
Lei Y; Department of Radiology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, #3002 SunGangXi Road, Shenzhen, 518035, China. .
Huang B; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, China. .; Department of Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, #106 Zhongshan 2Nd Road, Guangzhou, 510080, China. .
Pokaż więcej
Źródło:
Neuroradiology [Neuroradiology] 2024 Jan; Vol. 66 (1), pp. 81-92. Date of Electronic Publication: 2023 Nov 17.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Glioblastoma*/diagnostic imaging
Glioblastoma*/drug therapy
Glioblastoma*/genetics
Multiparametric Magnetic Resonance Imaging*
Telomerase*/genetics
Brain Neoplasms*/diagnostic imaging
Brain Neoplasms*/drug therapy
Brain Neoplasms*/genetics
Humans ; Magnetic Resonance Imaging/methods ; Temozolomide/therapeutic use ; Progression-Free Survival ; Retrospective Studies ; Radiomics ; Mutation
Czasopismo naukowe
Tytuł:
Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic Lung Adenocarcinoma.
Autorzy:
Yang G; Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Kim KH; Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Lee CG; Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Hong MH; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Kim HR; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Cho Y; Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Yoon HI; Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2024 Jan; Vol. 56 (1), pp. 115-124. Date of Electronic Publication: 2023 Aug 29.
Typ publikacji:
Journal Article
MeSH Terms:
Lung Neoplasms*/pathology
Adenocarcinoma of Lung*/radiotherapy
Humans ; Retrospective Studies ; Progression-Free Survival ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł:
Patient-reported outcomes and symptom clusters pattern of chemotherapy-induced toxicity in patients with early breast cancer.
Autorzy:
Wiranata, Juan Adrian (AUTHOR)
Hutajulu, Susanna Hilda (AUTHOR)
Astari, Yufi Kartika (AUTHOR)
Leo, Benedreky (AUTHOR)
Bintoro, Bagas Suryo (AUTHOR)
Hardianti, Mardiah Suci (AUTHOR)
Taroeno-Hariadi, Kartika Widayati (AUTHOR)
Kurnianda, Johan (AUTHOR)
Purwanto, Ibnu (AUTHOR)
Pokaż więcej
Źródło:
PLoS ONE. 2/23/2024, Vol. 19 Issue 2, p1-20. 20p.
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies